Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2019 (Filed November 21, 2019)
Headquarters: Melbourne, Australia
This filing serves as a procedural report to incorporate specific information by reference into the company's Registration Statements on Form S-8 (File No. 333-228671) and Form F-3 (Files No. 333-220886 and 333-231417). The document references "Appendix 3B" but does not contain the text of that appendix within this specific filing.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a cover sheet for incorporating external documents and does not contain a financial statement or performance summary.
Material Changes
No material changes regarding financial performance or operations are detailed in this specific filing text. The document focuses on regulatory compliance and the incorporation of reference materials.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, or details on contingencies. The primary content is the signature of the Executive Chairman, Geoffrey Kempler, authorizing the report.
Investor Verification Checklist
- Verify the contents of "Appendix 3B" referenced in Item 99.1, as the actual data is not included in this text.
- Review the referenced Registration Statements (Form S-8 File No. 333-228671; Form F-3 Files No. 333-220886 and 333-231417) for the specific information being incorporated.
- Confirm the company's current financial status through its most recent Form 20-F or quarterly reports, as this 6-K contains no financial data.